Sigilon Therapeutics, Inc.
SGTX · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $5,900 | $4,858 | $2,644 | $4,252 |
| % Growth | 21.4% | 83.7% | -37.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $5,900 | $4,858 | $2,644 | $4,252 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7,451 | $7,782 | $5,856 | $8,280 |
| G&A Expenses | $5,884 | $4,323 | $4,518 | $4,395 |
| SG&A Expenses | $5,884 | $4,323 | $4,518 | $4,395 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $81 | $4 | $0 | $58 |
| Operating Expenses | $13,335 | $12,105 | $10,374 | $12,675 |
| Operating Income | -$7,435 | -$7,247 | -$7,730 | -$8,423 |
| % Margin | -126% | -149.2% | -292.4% | -198.1% |
| Other Income/Exp. Net | -$71 | -$131 | $1,045 | -$248 |
| Pre-Tax Income | -$7,506 | -$7,378 | -$6,685 | -$8,671 |
| Tax Expense | $0 | $131 | -$1,045 | $248 |
| Net Income | -$7,506 | -$7,509 | -$5,640 | -$8,919 |
| % Margin | -127.2% | -154.6% | -213.3% | -209.8% |
| EPS | -0.23 | -0.23 | -0.17 | -0.28 |
| % Growth | 0% | -35.3% | 39.3% | – |
| EPS Diluted | -0.23 | -0.23 | -0.17 | -0.28 |
| Weighted Avg Shares Out | 32,467 | 32,467 | 32,462 | 32,400 |
| Weighted Avg Shares Out Dil | 32,467 | 32,467 | 32,462 | 32,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $433 | $476 | $404 | $300 |
| Interest Expense | $310 | $611 | $650 | $606 |
| Depreciation & Amortization | $310 | $795 | $1,695 | $674 |
| EBITDA | -$6,886 | -$6,452 | -$4,340 | -$7,749 |
| % Margin | -116.7% | -132.8% | -164.1% | -182.2% |